Website
News25/Ratings12
News · 26 weeks90+22%
2025-10-262026-04-19
Mix4090d
- Insider19(48%)
- SEC Filings8(20%)
- Other5(13%)
- Analyst4(10%)
- Earnings4(10%)
Latest news
25 items- PRInsmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2026 financial results on Thursday, May 7, 2026.Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss financial results and provide a business update.Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7
- INSIDERSEC Form 4 filed by Lewis William4 - INSMED Inc (0001104506) (Issuer)
- ANALYSTRaymond James initiated coverage on Insmed with a new price targetRaymond James initiated coverage of Insmed with a rating of Outperform and set a new price target of $200.00
- INSIDERSEC Form 4 filed by Lewis William4 - INSMED Inc (0001104506) (Issuer)
- SECInsmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Provides Clinical Update on Phase 2b CEDAR Study—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg tre
- INSIDERSEC Form 4 filed by Adsett Roger4 - INSMED Inc (0001104506) (Issuer)
- SECSEC Form DEFA14A filed by Insmed IncorporatedDEFA14A - INSMED Inc (0001104506) (Filer)
- SECSEC Form DEF 14A filed by Insmed IncorporatedDEF 14A - INSMED Inc (0001104506) (Filer)
- INSIDERSEC Form 4 filed by Smith Michael Alexander4 - INSMED Inc (0001104506) (Issuer)
- ANALYSTInsmed upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Insmed from Equal-Weight to Overweight and set a new price target of $212.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insmed IncorporatedSCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
- SECInsmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rates——In the Second Half of 2026, Insmed Plans to File a Supplemental NDA for ARIKAYCE with the FDA and Submit the Data to the PMDA in Japan to Support Potential Label Changes——Insmed to Host Investor Conference Call on Monday, March 23, 2026, at 8:00 AM ET—BRIDGEWATER, N.J., March 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of p
- INSIDERSEC Form 4 filed by Lewis William4 - INSMED Inc (0001104506) (Issuer)
- ANALYSTJefferies resumed coverage on InsmedJefferies resumed coverage of Insmed with a rating of Buy
- SECSEC Form 144 filed by Insmed Incorporated144 - INSMED Inc (0001104506) (Subject)
- INSIDERChair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,562,328 worth of shares (10,699 units at $146.03) (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Sharoky Melvin Md gifted 100 shares, decreasing direct ownership by 0.04% to 242,776 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- PRInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence
- INSIDERDirector Sharoky Melvin Md gifted 1,072 shares and received a gift of 972 shares, decreasing direct ownership by 0.44% to 242,876 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Legal Officer Smith Michael Alexander exercised 20,248 shares at a strike of $17.07 and sold $3,859,157 worth of shares (24,774 units at $155.77), decreasing direct ownership by 8% to 51,871 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Brennan David R gifted 6,000 shares, decreasing direct ownership by 9% to 60,933 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,615,257 worth of shares (10,699 units at $150.97) (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- SECSEC Form 10-K filed by Insmed Incorporated10-K - INSMED Inc (0001104506) (Filer)